Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies

Aim Optimal management of bladder cancer requires an accurate, standardised and timely pathological diagnosis, and close communication between surgeons and pathologists. Here, we provide an update on pathology reporting standards of transurethral resections of the bladder and cystectomies. Methods We reviewed recent literature, focusing on developments between 2013 and 2021. Results Published reporting standards developed by pathology organizations have improved diagnosis and treatment. Tumor sub-staging and subtyping has gained increased attention. Lymph nodes continue to be an area of debate, and their staging has seen minor modifications. Several tasks, particularly regarding specimen preparation (grossing), are not yet standardized and offer opportunity for improvement. Molecular classification is rapidly evolving, but currently has only limited impact on management. Conclusion Pathological reporting of bladder cancer is continuously evolving and remains challenging in some areas. This review provides an overview of recent major developments, with a particular focus on published reporting standards.

Automated summary

The optimal management of bladder cancer requires accurate, standardized, and timely pathological diagnosis, as well as close communication between surgeons and pathologists. This review highlights the importance of published reporting standards in improving diagnosis and treatment, as well as the evolving nature of pathological reporting in bladder cancer. Areas such as tumor sub-staging, lymph node staging, and specimen preparation offer opportunities for further standardization and improvement.